BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Streubel G, Schrepfer S, Kallus H, Parnitzke U, Wulff T, Hermann F, Borgmann M, Hamm S. Histone deacetylase inhibitor resminostat in combination with sorafenib counteracts platelet-mediated pro-tumoral effects in hepatocellular carcinoma. Sci Rep 2021;11:9587. [PMID: 33953226 DOI: 10.1038/s41598-021-88983-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Bär SI, Dittmer A, Nitzsche B, Ter-Avetisyan G, Fähling M, Klefenz A, Kaps L, Biersack B, Schobert R, Höpfner M. Chimeric HDAC and the cytoskeleton inhibitor broxbam as a novel therapeutic strategy for liver cancer. Int J Oncol 2022;60:73. [PMID: 35485292 DOI: 10.3892/ijo.2022.5363] [Reference Citation Analysis]
2 Wolinska E, Skrzypczak M. Epigenetic Changes Affecting the Development of Hepatocellular Carcinoma. Cancers (Basel) 2021;13:4237. [PMID: 34439391 DOI: 10.3390/cancers13164237] [Reference Citation Analysis]